EGFR genomic alterations in cancer: Prognostic and predictive values

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 3, 2011, Pages 879-887

  Bronte, Giuseppe ^a   Terrasi, Marianna ^a   Rizzo, Sergio ^a   Sivestris, Nicola ^b   Ficorella, Corrado ^c   Cajozzo, Massimo ^a   Di Gaudio, Francesca ^d   Gulotta, Gaspare ^d   Siragusa, Sergio ^e   Gebbia, Nicola ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

EGFR; Monoclonal antibodies; Review; Tyrosine kinase inhibitors

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; NERATINIB; PACLITAXEL; PANITUMUMAB; PELITINIB; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL STRAIN 3T3; COLORECTAL CANCER; DRUG PROTEIN BINDING; GENE DOSAGE; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; CHEMISTRY; GENETICS; MUTATION; PROGNOSIS;

GENE DOSAGE; HUMANS; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79960370663     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. J. Mendelsohn and J. Baselga: The EGF receptor family as targets for cancer therapy. Oncogene, 19(56), 6550-65 (2000) (Pubitemid 32197693)
2. A. W. Burgess, H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X. Sliwkowski, C. W. Ward and S. Yokoyama: An open-andshut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell, 12(3), 541-52 (2003) (Pubitemid 37222478)
3. L. A. Bazley and W. J. Gullick: The epidermal growth factor receptor family. Endocr Relat Cancer, 12 Suppl 1, S17-27 (2005) (Pubitemid 41395411)
4. A. Kumar, E. T. Petri, B. Halmos and T. J. Boggon: Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol, 26(10), 1742-51 (2008)
5. D. S. Salomon, R. Brandt, F. Ciardiello and N. Normanno: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19(3), 183-232 (1995)
6. R. I. Nicholson, J. M. Gee and M. E. Harper: EGFR and cancer prognosis. Eur J Cancer, 37 Suppl 4, S9-15 (2001) (Pubitemid 32938124)
7. J. P. Spano, G. Milano, S. Vignot and D. Khayat: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol, 66(1), 21-30 (2008)
8. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau and E. Van Cutsem: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med, 351(4), 337-45 (2004) (Pubitemid 38944402)
9. H. J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, Z. Tsuchihashi, D. J. Mauro and E. K. Rowinsky: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol, 24(30), 4914-21 (2006) (Pubitemid 46630920)
10. L. B. Saltz, N. J. Meropol, P. J. Loehrer, Sr., M. N. Needle, J. Kopit and R. J. Mayer: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22(7), 1201-8 (2004) (Pubitemid 41079832)
11. K. Y. Chung, J. Shia, N. E. Kemeny, M. Shah, G. K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, L. Schwartz, D. S. Klimstra, D. Fridman, D. P. Kelsen and L. B. Saltz: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23(9), 1803-10 (2005) (Pubitemid 46211358)
12. J. Berlin, J. Posey, S. Tchekmedyian, E. Hu, D. Chan, I. Malik, L. Yang, R. G. Amado and J. R. Hecht: Panitumumab with irinotecan/leucovorin/5- fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer, 6(6), 427-32 (2007) (Pubitemid 46658516)
13. J. R. Hecht, E. Mitchell, M. A. Neubauer, H. A. Burris, 3rd, P. Swanson, T. Lopez, G. Buchanan, M. Reiner, J. Gansert and J. Berlin: Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res, 16(7), 2205-13 (2010)
14. M. Agulnik, G. Da Cunha Santos, D. Hedley, T. Nicklee, P. P. Dos Reis, J. Ho, G. R. Pond, H. Chen, S. Chen, Y. Shyr, E. Winquist, D. Soulieres, E. X. Chen, J. A. Squire, P. Marrano, S. Kamel-Reid, J. Dancey, L. L. Siu and M. S. Tsao: Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol, 25(16), 2184-90 (2007) (Pubitemid 46954641)
15. F. Cappuzzo: Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. J Thorac Oncol, 2(5 Suppl), S12-4 (2007) (Pubitemid 47181732)
16. J. Y. Douillard, F. A. Shepherd, V. Hirsh, T. Mok, M. A. Socinski, R. Gervais, M. L. Liao, H. Bischoff, M. Reck, M. V. Sellers, C. L. Watkins, G. Speake, A. A. Armour and E. S. Kim: Molecular predictors of outcome with gefitinib and docetaxel in previously treated nonsmall-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 28(5), 744-52 (2010)
17. D. A. Haas-Kogan, M. D. Prados, K. R. Lamborn, T. Tihan, M. S. Berger and D. Stokoe: Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle, 4(10), 1369-72 (2005) (Pubitemid 41437124)
18. S. W. Han, T. Y. Kim, P. G. Hwang, S. Jeong, J. Kim, I. S. Choi, D. Y. Oh, J. H. Kim, D. W. Kim, D. H. Chung, S. A. Im, Y. T. Kim, J. S. Lee, D. S. Heo, Y. J. Bang and N. K. Kim: Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol, 23(11), 2493-501 (2005) (Pubitemid 47050839)
19. R. S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. E. Johnson, A. Sandler, M. G. Kris, H. T. Tran, P. Klein, X. Li, D. Ramies, D. H. Johnson and V. A. Miller: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 23(25), 5892-9 (2005)
20. S. Kakiuchi, Y. Daigo, N. Ishikawa, C. Furukawa, T. Tsunoda, S. Yano, K. Nakagawa, T. Tsuruo, N. Kohno, M. Fukuoka, S. Sone and Y. Nakamura: Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet, 13(24), 3029-43 (2004) (Pubitemid 40045258)
21. M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, D. Zennaro, C. Lagrasta, N. Campanini, E. Spiritelli, R. Camisa, F. Grossi, G. Rindi, V. Franciosi and A. Ardizzoni: Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Clin Cancer Res, 13(21), 6518-26 (2007) (Pubitemid 350075043)
22. I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers and P. S. Mischel: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 353(19), 2012-24 (2005) (Pubitemid 41609094)
23. M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski and W. Parulekar: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25(15), 1960-6 (2007) (Pubitemid 46972777)
24. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara and P. Bonomi: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 22(16), 3238-47 (2004) (Pubitemid 41103678)
25. J. N. Rich, B. K. Rasheed and H. Yan: EGFR mutations and sensitivity to gefitinib. N Engl J Med, 351(12), 1260-1; author reply 1260-1 (2004)
26. M. S. Tsao, A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. Da Cunha Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater and F. A. Shepherd: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 353(2), 133-44 (2005) (Pubitemid 41058345)
27. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn, Jr., W. A. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. R. Pereira, T. Ciuleanu, J. Von Pawel, C. Watkins, A. Flannery, G. Ellison, E. Donald, L. Knight, D. Parums, N. Botwood and B. Holloway: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5034-42 (2006) (Pubitemid 46631407)
28. L. R. Bailey, M. G. Kris and M. E. A. Wolf: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD1939) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL1 and 2 Proc Am Assoc Cancer, 44, 1362 (abstract LB-170) (2003)
29. J. Shia, D. S. Klimstra, A. R. Li, J. Qin, L. Saltz, J. Teruya-Feldstein, M. Akram, K. Y. Chung, D. Yao, P. B. Paty, W. Gerald and B. Chen: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol, 18(10), 1350-6 (2005) (Pubitemid 41348654)
30. T. Mitsudomi and Y. Yatabe: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci, 98(12), 1817-24 (2007) (Pubitemid 350002184)
31. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris and H. Varmus: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101(36), 13306-11 (2004) (Pubitemid 39209661)
32. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-39 (2004) (Pubitemid 38637993)
33. J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson and M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-500 (2004) (Pubitemid 38720929)
34. K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson and M. X. Sliwkowski: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res, 66(16), 8163-71 (2006) (Pubitemid 44299184)
35. C. H. Yun, T. J. Boggon, Y. Li, M. S. Woo, H. Greulich, M. Meyerson and M. J. Eck: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11(3), 217-27 (2007) (Pubitemid 46349842)
36. D. M. Jackman, B. Y. Yeap, N. I. Lindeman, P. Fidias, M. S. Rabin, J. Temel, A. T. Skarin, M. Meyerson, A. J. Holmes, A. M. Borras, B. Freidlin, P. A. Ostler, J. Lucca, T. J. Lynch, B. E. Johnson and P. A. Janne: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol, 25(7), 760-6 (2007) (Pubitemid 350002874)
37. G. J. Riely, K. A. Politi, V. A. Miller and W. Pao: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 12(24), 7232-41 (2006) (Pubitemid 46095394)
38. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J. L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M. A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J. M. Sanchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M. A. Molina, J. J. Sanchez and M. Taron: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 361(10), 958-67 (2009)
39. J. M. Sun, Y. W. Won, S. T. Kim, J. H. Kim, Y. L. Choi, J. Lee, Y. H. Park, J. S. Ahn, K. Park and M. J. Ahn: The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol (2010)
40. D. M. Jackman, V. A. Miller, L. A. Cioffredi, B. Y. Yeap, P. A. Janne, G. J. Riely, M. G. Ruiz, G. Giaccone, L. V. Sequist and B. E. Johnson: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res, 15(16), 5267-73 (2009)
41. E. S. Kim, V. Hirsh, T. Mok, M. A. Socinski, R. Gervais, Y. L. Wu, L. Y. Li, C. L. Watkins, M. V. Sellers, E. S. Lowe, Y. Sun, M. L. Liao, K. Osterlind, M. Reck, A. A. Armour, F. A. Shepherd, S. M. Lippman and J. Y. Douillard: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372(9652), 1809-18 (2008)
42. T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour and M. Fukuoka: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361(10), 947-57 (2009)
43. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen and B. Halmos: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352(8), 786-92 (2005) (Pubitemid 40271173)
44. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris and H. Varmus: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2(3), e73 (2005)
45. S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R. G. Tompkins, T. J. Lynch, M. Toner and D. A. Haber: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 359(4), 366-77 (2008)
46. E. L. Kwak, R. Sordella, D. W. Bell, N. Godin-Heymann, R. A. Okimoto, B. W. Brannigan, P. L. Harris, D. R. Driscoll, P. Fidias, T. J. Lynch, S. K. Rabindran, J. P. McGinnis, A. Wissner, S. V. Sharma, K. J. Isselbacher, J. Settleman and D. A. Haber: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A, 102(21), 7665-70 (2005) (Pubitemid 40741028)
47. L. V. Sequist: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist, 12(3), 325-30 (2007) (Pubitemid 46556799)
48. C. H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K. K. Wong, M. Meyerson and M. J. Eck: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A, 105(6), 2070-5 (2008) (Pubitemid 351439466)
49. N. Godin-Heymann, I. Bryant, M. N. Rivera, L. Ulkus, D. W. Bell, D. J. Riese, 2nd, J. Settleman and D. A. Haber: Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res, 67(15), 7319-26 (2007) (Pubitemid 47206561)
50. L. Regales, M. N. Balak, Y. Gong, K. Politi, A. Sawai, C. Le, J. A. Koutcher, D. B. Solit, N. Rosen, M. F. Zakowski and W. Pao: Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One, 2(8), e810 (2007)
51. D. Li, T. Shimamura, H. Ji, L. Chen, H. J. Haringsma, K. McNamara, M. C. Liang, S. A. Perera, S. Zaghlul, C. L. Borgman, S. Kubo, M. Takahashi, Y. Sun, L. R. Chirieac, R. F. Padera, N. I. Lindeman, P. A. Janne, R. K. Thomas, M. L. Meyerson, M. J. Eck, J. A. Engelman, G. I. Shapiro and K. K. Wong: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell, 12(1), 81-93 (2007) (Pubitemid 47001787)
52. W. Pao and V. A. Miller: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol, 23(11), 2556-68 (2005)
53. H. Kimura, Y. Fujiwara, T. Sone, H. Kunitoh, T. Tamura, K. Kasahara and K. Nishio: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci, 97(7), 642-8 (2006) (Pubitemid 44056613)
54. T. D. Barber, B. Vogelstein, K. W. Kinzler and V. E. Velculescu: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med, 351(27), 2883 (2004) (Pubitemid 40051921)
55. M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio, M. Gambacorta, S. Siena and A. Bardelli: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 6(5), 279-86 (2005) (Pubitemid 40590264)
56. S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark, C. Namgyal, T. Kawasaki, K. Kinsella, A. L. Michelini, P. C. Enzinger, M. H. Kulke, D. P. Ryan, M. Loda and C. S. Fuchs: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res, 11(18), 6650-6 (2005) (Pubitemid 41339006)
57. B. R. Voldborg, L. Damstrup, M. Spang-Thomsen and H. S. Poulsen: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 8(12), 1197-206 (1997) (Pubitemid 28164074)
58. I. E. Garcia De Palazzo, G. P. Adams, P. Sundareshan, A. J. Wong, J. R. Testa, D. D. Bigner and L. M. Weiner: Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res, 53(14), 3217-20 (1993) (Pubitemid 23223283)
59. P. H. Huang, W. K. Cavenee, F. B. Furnari and F. M. White: Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle, 6(22), 2750-4 (2007) (Pubitemid 350277165)
60. I. A. Lorimer: Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets, 2(2), 91-102 (2002) (Pubitemid 34625478)
61. A. M. Sonabend, K. Dana and M. S. Lesniak: Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther, 7(12 Suppl), S45-50 (2007)
62. F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, L. Chin, R. A. De Pinho and W. K. Cavenee: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev, 21(21), 2683-710 (2007) (Pubitemid 350070717)
63. N. Sugawa, A. J. Ekstrand, C. D. James and V. P. Collins: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A, 87(21), 8602-6 (1990)
64. C. A. Learn, T. L. Hartzell, C. J. Wikstrand, G. E. Archer, J. N. Rich, A. H. Friedman, H. S. Friedman, D. D. Bigner and J. H. Sampson: Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res, 10(9), 3216-24 (2004) (Pubitemid 38619703)
65. H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, R. K. Thomas, H. Sasaki, J. W. Horner, M. Eck, A. Mitchell, Y. Sun, R. Al-Hashem, R. T. Bronson, S. K. Rabindran, C. M. Discafani, E. Maher, G. I. Shapiro, M. Meyerson and K. K. Wong: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 103(20), 7817-22 (2006)
66. M. Azuma, K. D. Danenberg, S. Iqbal, A. El-Khoueiry, P. V. Danenberg, W. Fazzone, R. D. Ladner and H. J. Lenz: EGFR and EGFR VIII gene expression in metastatic colorectal cancer (mCRC). In: Gastrointestinal Cancers Symposium. (2006)
67. V. Martin, L. Mazzucchelli and M. Frattini: An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol, 62(4), 314-24 (2009)
68. J. J. Carlson, L. P. Garrison, S. D. Ramsey and D. L. Veenstra: Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 135(11), 1483-93 (2009)
69. F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, W. A. Franklin, L. Crino, A. F. Gazdar, P. A. Bunn, Jr. and F. R. Hirsch: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptorpositive non-small-cell lung cancer patients. J Clin Oncol, 23(22), 5007-18 (2005) (Pubitemid 46224007)
70. H. Sasaki, K. Endo, K. Okuda, O. Kawano, N. Kitahara, H. Tanaka, A. Matsumura, K. Iuchi, M. Takada, M. Kawahara, T. Kawaguchi, H. Yukiue, T. Yokoyama, M. Yano and Y. Fujii: Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol, 134(5), 569-77 (2008) (Pubitemid 351422610)
71. M. Varella-Garcia, T. Mitsudomi, Y. Yatabe, T. Kosaka, E. Nakajima, A. C. Xavier, M. Skokan, C. Zeng, W. A. Franklin, P. A. Bunn, Jr. and F. R. Hirsch: EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol, 4(3), 318-25 (2009)
72. J. Amann, S. Kalyankrishna, P. P. Massion, J. E. Ohm, L. Girard, H. Shigematsu, M. Peyton, D. Juroske, Y. Huang, J. Stuart Salmon, Y. H. Kim, J. R. Pollack, K. Yanagisawa, A. Gazdar, J. D. Minna, J. M. Kurie and D. P. Carbone: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res, 65(1), 226-35 (2005) (Pubitemid 40070814)
73. R. Morinaga, I. Okamoto, Y. Fujita, T. Arao, M. Sekijima, K. Nishio, H. Ito, M. Fukuoka, J. Kadota and K. Nakagawa: Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Sci, 99(12), 2455-60 (2008)
74. H. Sasaki, S. Shimizu, K. Okuda, O. Kawano, H. Yukiue, M. Yano and Y. Fujii: Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer, 64(3), 295-300 (2009)
75. T. Takano and Y. Ohe: Erlotinib in lung cancer. N Engl J Med, 353(16), 1739-41; author reply 1739-41 (2005)
76. M. Taron, Y. Ichinose, R. Rosell, T. Mok, B. Massuti, L. Zamora, J. L. Mate, C. Manegold, M. Ono, C. Queralt, T. Jahan, J. J. Sanchez, M. Sanchez-Ronco, V. Hsue, D. Jablons, J. M. Sanchez and T. Moran: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res, 11(16), 5878-85 (2005) (Pubitemid 41170316)
77. S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B. E. Johnson and P. A. Janne: Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res, 64(20), 7241-4 (2004) (Pubitemid 39372059)
78. T. Sauer, M. G. Guren, T. Noren and S. Dueland: Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology, 47(6), 560-4 (2005) (Pubitemid 41775177)
79. A. Lievre, J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Cote, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca and P. Laurent-Puig: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66(8), 3992-5 (2006)
80. A. Sartore-Bianchi, M. Moroni, S. Veronese, C. Carnaghi, E. Bajetta, G. Luppi, A. Sobrero, C. Barone, S. Cascinu, G. Colucci, E. Cortesi, M. Nichelatti, M. Gambacorta and S. Siena: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol, 25(22), 3238-45 (2007) (Pubitemid 47325607)
81. S. Khambata-Ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris, 3rd, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark and D. J. Mauro: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, 25(22), 3230-7 (2007) (Pubitemid 47325606)